A group of conditions, not one visual future
RP is a group of inherited retinal diseases that affect light-sensitive cells. Night-vision and peripheral-vision difficulties are common features, but onset, progression and remaining vision vary. Clinical and genetic information help characterize an individual condition. [1]
A person’s acuity in a bright clinic does not describe every problem with dark adaptation or mobility. Explain the environments and tasks affected as well as the results of a letter-chart test. [2]
Lighting
Dim conditions may reveal difficulties that bright scenes do not.
Field of view
Peripheral changes can affect locating objects and mobility.
Genetic diversity
The same broad label does not mean the same course or treatment.
Terms in this guide
- Photoreceptor
- A retinal cell involved in detecting light.
- Genotype
- A person’s genetic findings relevant to a condition.
One condition. Different experiences.
These original examples separate two aspects of vision. They are not early/middle/late RP stages or a genetic diagnosis.
Original VisualSim schematic illustrations, informed by the cited clinical descriptions. These are not study figures, patient recordings or validated severity levels. Clinical basis: source 1. Artwork: © VisualSim; see image provenance.
Photoreceptors and inherited differences
Changes in genes involved in retinal function can affect photoreceptors and other retinal processes. Assessment may include retinal examination, imaging, visual-field testing, electroretinography and genetic testing or counselling. [1]
The simulator reduces dim-area visibility and changes a peripheral effect. It cannot reproduce an individual field defect, the time needed for dark adaptation, light perception thresholds or the functional differences between genotypes.
What can look similar?
Other causes of night difficulty
Several eye conditions can make dim lighting difficult. A night scene cannot identify RP by itself.
Glaucoma
Peripheral symptoms can overlap in description even though the disease process and assessment differ.
Sudden new symptoms
An established inherited diagnosis does not exclude an unrelated urgent eye problem.
Similar-looking symptoms can have different causes. A matching picture cannot establish a diagnosis.
What an assessment may involve
Ask what the examination and tests show about your particular retinal condition. Genetic counselling can explain the meaning and limitations of a result, implications for relatives and whether genotype-specific care or trials are relevant. [2]
- Describe the settingExplain lighting changes, night mobility and peripheral tasks.
- Understand the testsAsk how structural, functional and genetic findings fit together.
- Make a practical planDiscuss rehabilitation, monitoring and appropriate research opportunities.
What may help—and what is still being studied
Vision rehabilitation, aids and support can help with everyday goals. Treatment options are not the same for every inherited retinal condition. Genetic and retinal findings are important when considering targeted therapies. [1]
Voretigene neparvovec is authorized for a specific group with confirmed biallelic RPE65-associated retinal dystrophy and sufficient viable retinal cells. It is not a general treatment for all RP. Benefits, surgical risks, eligibility and availability require a specialist discussion. [3]
Older supplement recommendations need reassessment against newer evidence. The AAO’s 2025 report found no high-quality evidence supporting dietary supplements for RP. An older institutional page is not enough to justify starting high-dose vitamins; discuss the evidence and risks with your retinal specialist. [5]
What this can mean for daily life
Plan for changing light
Describe moving between bright and dim settings. Ask a rehabilitation professional about strategies appropriate to your environment.
Access education and mobility support
Discuss school, work, orientation and mobility goals. Support should be matched to what you want to do, not a single simulator setting.
Bring a clearer description to your appointment
Choose the questions you want to discuss. These choices stay in this page’s memory.
Research, with the context left in
Genotype-specific trials are an example of why research populations matter. A treatment studied in one molecular diagnosis should not be presented as a cure for all RP.
What the evidence supports
RP is genetically diverse, so genotype, viable retina and functional goals matter more than a single tunnel image. RPE65 gene therapy has controlled-trial evidence in a specific molecular diagnosis and is not a treatment for all RP. Newer specialist evidence does not support routine dietary supplements as a general disease-slowing treatment. Trials, regulatory review and authorized care must remain clearly distinct.
How we select and interpret researchRussell et al.: Voretigene neparvovec for RPE65-mediated inherited retinal dystrophy
People with confirmed biallelic RPE65 variants and sufficient viable retina improved on a standardized multi-luminance mobility task compared with controls at one year. Outcome graders were masked.
Limits and applicability: Small rare-disease trial, two US sites, open-label treatment allocation and sponsor funding. Low-light navigation benefit is not a promise of normal vision, retinal regeneration or applicability to all RP.
How to read this evidence: Controlled evidence supports functional low-light mobility benefit in the studied molecular subgroup; confidence should not be transferred to unrelated RP genotypes.
European Medicines Agency: Luxturna indication, evidence and safety
Eligibility requires vision loss from confirmed biallelic RPE65-associated inherited retinal dystrophy and sufficient viable retinal cells. Treatment involves specialist subretinal surgery, with ocular risks and long-term follow-up.
Limits and applicability: The authorization does not include every condition called RP. Availability, funding, surgical suitability and remaining retinal function require individual specialist assessment.
How to read this evidence: Authoritative for the EU authorization and eligibility requirements; not an independent head-to-head trial.
Jain et al., AAO: Dietary supplementation for retinitis pigmentosa
The panel found no high-quality evidence supporting dietary supplementation for RP. Apparent benefits often came from secondary outcomes, subgroups, post hoc analyses or uncertain clinical significance.
Limits and applicability: Existing studies were single-center and relatively old. Different nutrients, genotypes and endpoints cannot be combined into a universal efficacy claim. This is not a reason to stop prescribed treatment without discussing it with a clinician.
How to read this evidence: A stronger treatment anchor than unsourced supplement advice because the panel reviewed study methods and clinical relevance; absence of high-quality evidence is not proof every future intervention will fail.
Comander et al.: RP natural history, genotype, vitamin A/E and an electroretinogram biomarker
After incorporating baseline electroretinogram timing and additional data, the previously reported general vitamin A benefit was not detectable. The adverse signal from high-dose vitamin E persisted. Genotype and baseline function helped explain progression differences.
Limits and applicability: A secondary reanalysis of older cohorts, with subgroup and measurement limitations. Results do not establish a precise prognosis for a person or validate a simulator setting as a progression marker.
How to read this evidence: Important evidence that changes interpretation of an influential historical trial; lower certainty for unplanned genotype subgroups than for a new prespecified randomized comparison.
Marques et al.: Portuguese ophthalmology and human-genetics guidelines for inherited retinal dystrophy testing
Recommends integrating clinical phenotyping, molecular testing and genetic counselling. Results can clarify diagnosis, inheritance and eligibility for genotype-specific treatment or trials; interpretation and family implications require explanation.
Limits and applicability: A national guideline rather than a universal funding policy. Testing methods, access and yield differ, and an uncertain or negative result does not exclude inherited retinal disease.
How to read this evidence: Useful specialist consensus for diagnostic pathways and counselling; not randomized evidence that a test itself improves vision.
Questions researchers still need to answer
- Has my diagnosis been genetically characterized, and what does an uncertain or negative result mean?
- Does a trial require a particular gene, viable retinal structure, age or remaining level of vision?
- Is an advertised intervention approved, in regulatory review or still experimental?
- Do outcomes measure daily visual function and long-term safety, as well as retinal structure or electrical responses?
These are editorial interpretations, not formal GRADE ratings or independent clinical review. A large sample, recent date or well-known publisher does not make every claim certain.
Trusted places to go next
Selected clinical references, research and support organizations. Each link explains who it is for.
Foundation Fighting Blindness
Research education and patient resources.
EMA: Luxturna
Indication, evidence and risks for one genotype-specific therapy.
Organizations & ways to connect
Selected charities, professional organizations and communities, with their scope and region. Official pages checked 24 October 2026. Community discussions are peer support; each external service has its own privacy and moderation rules.
Retina UK
Research funding, a helpline, genetics education and local/online support. Its Information & Support Facebook group is a non-medical peer community; advice shared there is not clinical evidence.
Connections listed by the organization.
Foundation Fighting Blindness
Funds retinal research, provides education and connects people through local chapters. Trial or registry participation is optional and handled on the organization’s own service, not through VisualSim.
Connections listed by the organization.
Fighting Blindness
Retinal research, Target 5000 information, counselling and support groups for people with sight loss and their families. Peer groups provide support rather than a personal treatment plan.
Connections listed by the organization.
Fighting Blindness Canada
Funds retinal research and provides education, webinars and community events, including inherited-retinal-disease and AMD Coffee Connections. Community discussions are non-medical peer support.
Connections listed by the organization.
Retina International
A route to national retinal-disease groups, patient education, advocacy and research participation information. Member services vary by country; this is a global directory rather than a claim that every local group has been reviewed.
Connections listed by the organization.
Retina South Africa
Patient advocacy and counselling, retinal-research support and assistance navigating genetic testing and referrals. Also listed by Retina International as a national member organization.
Connections listed by the organization.
Questions you may still have
Does everyone with RP see a dark tunnel?
No. Lighting, visual-field pattern and awareness vary. This is a limited illustration.
Can a slider predict progression?
No. These settings do not represent a clinical stage or forecast of future sight.
Is gene therapy available for all RP?
No. Current targeted treatment eligibility is specific; the RPE65 indication is one example. [3]
Sources, image credits and review status
Compiled by VisualSim from clinical references and published research. Sources checked 24 October 2026. Independent clinical review has not been recorded; no named clinical reviewer or clinical validation is claimed. Research evidence and its limitations are linked below.
- National Eye Institute. Retinitis pigmentosa. Clinical information; sources checked 24 October 2026.
- RNIB. Retinitis pigmentosa. Clinical information; sources checked 24 October 2026.
- European Medicines Agency. Luxturna: indication, evidence and risks. Regulatory scope is specific to the stated condition, viable retina and jurisdiction.
- US FDA. LUXTURNA. Clinical information; sources checked 24 October 2026.
- Jain et al. Dietary Supplementation for Retinitis Pigmentosa: An American Academy of Ophthalmology Report (2025). Clinical information; sources checked 24 October 2026.
- Russell et al.: Voretigene neparvovec for RPE65-mediated inherited retinal dystrophy (2017). Randomized, open-label, controlled phase 3 trial; 31 randomized participants, 29 in modified intention-to-treat analysis
- Comander et al.: RP natural history, genotype, vitamin A/E and an electroretinogram biomarker (2023). Genetic and biomarker reanalysis of banked samples and longitudinal outcomes from earlier vitamin trials
- Marques et al.: Portuguese ophthalmology and human-genetics guidelines for inherited retinal dystrophy testing (2025). Joint professional clinical practice guidelines for genetic testing and counselling
The simulator helps people communicate an experience. It cannot diagnose a condition, measure a visual field, or establish that someone is safe to drive.